InsiderClue
← All stocks

CRESCENT BIOPHARMA, INC.

CBIO Net buying
CIK 0001253689 #2943 in the set updated 22 Sep 2026
Bought (120 mo)
$46.91M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$16.73M
$1.51M on a plan · $1.36M straight out of an exercise
Sold at will
$13.86M
34 of 60 sales
Net
+$30.18M
+$33.05M against sales at will

By person

29 insiders · 107 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Fairmount Funds Management LLC entity
Director
$30.61M (2)
—
+$30.61M
3,601,316
$60.18M
+159.5%
SANDELL SCOTT D
10% owner
—
$13.04M (14)
−$13.04M
11,326,237
$189.26M
−24.2%
BVF PARTNERS L P/IL entity
10% owner
$11.17M (9)
—
+$11.17M
62,383
$1.04M
—
Invus Public Equities, L.P.
10% owner
$3.95M (8)
$488.75K (9)
+$3.46M
6,317,565
$105.57M
−3.7%
Brumm Joshua T
Chief Executive Officer
—
$920.84K (3) scheduled
−$920.84K
271,765
$4.54M
+1.3%
Rock Edwin
Chief Medical Officer
$725.58K (7)
—
+$725.58K
680,403
$11.37M
—
McNeill Jonathan
President and COO
—
$446.91K (3) scheduled
−$446.91K
134,588
$2.25M
+0.3%
Hahn Brian M.
SVP Finance, CFO
$25.53K (2)
$359.38K (3) scheduled
−$333.84K
70,643
$1.18M
+401.5%
King Rachel K.
Director
—
$329.13K (1) scheduled
−$329.13K
690,336
$11.54M
+88.4%
Magnani John L.
SVP of Research, CSO
$52.70K (1)
$353.73K (4)
−$301.03K
370,923
$6.20M
+289.5%
JUNIUS DANIEL M
Director
$214.05K (5)
—
+$214.05K
98,459
$1.65M
—
BARRETT M JAMES
Director
—
$169.89K (2) scheduled
−$169.89K
9,089,041
$151.88M
+5.9%
BARRIS PETER J
10% owner
—
$169.89K (2) scheduled
−$169.89K
9,089,041
$151.88M
+5.9%
NEW ENTERPRISE ASSOCIATES 10 L P entity
10% owner
—
$169.89K (2) scheduled
−$169.89K
4,995,664
$83.48M
+11.2%
Thackray Helen M.
SVP Clinical Development, CMO
—
$139.44K (6)
−$139.44K
183,115
$3.06M
+14.0%
Andrews Patricia S
Director
$82.00K (1)
—
+$82.00K
58,608
$979.34K
—
Pinkas Jan
Chief Scientific Officer
—
$34.95K (2) scheduled
−$34.95K
21,581
$360.62K
+2,016%
Im Ellie Eunkyung
Chief Medical Officer
—
$33.08K (2) scheduled
−$33.08K
21,446
$358.36K
+977.7%
Bispham Barbara Harlin
See Remarks
—
$33.01K (2) scheduled
−$33.01K
18,710
$312.64K
+780.1%
Semerjian Harout
Chief Executive Officer
$32.25K (1)
—
+$32.25K
25,000
$417.75K
—
Scalzo Richard William
Chief Financial Officer
—
$30.17K (2) scheduled
−$30.17K
19,730
$329.69K
+892.5%
PEARSON TIMOTHY R
Director
$25.03K (1)
—
+$25.03K
24,650
$411.90K
—
Johnson Bruce S
SVP & Chief Commercial Officer
$21.20K (1)
—
+$21.20K
138,980
$2.32M
+10.8%
Lynch Ryan
See Remarks
—
$12.66K (2) scheduled
−$12.66K
13,631
$227.77K
+596.2%
Girard Armand
SVP, Chief Business Officer
$6.83K (1)
$2.55K (1)
+$4.28K
29,161
$487.28K
—
Doughty Christopher Grant
Chief Business Officer
—
—
—
62,194
$1.04M
+57.5%
Koenig Scott
Director
—
—
—
36,750
$614.09K
—
Goldberg Mark Alan
Director
—
—
—
36,325
$606.99K
+216.0%
Jackson Scott Thomas
Director
—
—
—
5,250
$87.73K
—

No percentages here. This company's share count has moved by a factor of 4.6 over the window, from 13,892,516 to 64,532,091 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Individual transactions

107
Insider
Date
Role
Action
Shares
Price
Amount
McNeill Jonathan
18 Sep 2026
President and COO
Sold on a plan
3,839
$16.71
$64.15K
Brumm Joshua T
18 Sep 2026
Chief Executive Officer
Sold on a plan
7,837
$16.71
$130.96K
McNeill Jonathan
16 Sep 2026
President and COO
Sold on a plan
731
$17.90
$13.08K
Brumm Joshua T
16 Sep 2026
Chief Executive Officer
Sold on a plan
1,610
$17.90
$28.82K
Bispham Barbara Harlin
16 Sep 2026
See Remarks
Sold on a plan
620
$17.90
$11.10K
Scalzo Richard William
16 Sep 2026
Chief Financial Officer
Sold on a plan
568
$17.90
$10.17K
Im Ellie Eunkyung
16 Sep 2026
Chief Medical Officer
Sold on a plan
623
$17.90
$11.15K
Pinkas Jan
16 Sep 2026
Chief Scientific Officer
Sold on a plan
658
$17.90
$11.78K
Lynch Ryan
16 Sep 2026
See Remarks
Sold on a plan
240
$17.90
$4.30K
Fairmount Funds Management LLC
16 Jul 2026
Director
Buy indirect
853,450
$14.50
$12.38M
Brumm Joshua T
22 Jun 2026
Chief Executive Officer
Sold on a plan
42,305
$17.99
$761.07K
McNeill Jonathan
22 Jun 2026
President and COO
Sold on a plan
20,549
$17.99
$369.68K
Im Ellie Eunkyung
22 Jun 2026
Chief Medical Officer
Sold on a plan
1,219
$17.99
$21.93K
Bispham Barbara Harlin
22 Jun 2026
See Remarks
Sold on a plan
1,218
$17.99
$21.91K
Scalzo Richard William
22 Jun 2026
Chief Financial Officer
Sold on a plan
1,112
$17.99
$20.00K
Pinkas Jan
22 Jun 2026
Chief Scientific Officer
Sold on a plan
1,288
$17.99
$23.17K
Lynch Ryan
22 Jun 2026
See Remarks
Sold on a plan
465
$17.99
$8.37K
Fairmount Funds Management LLC
4 Dec 2025
Director
Buy indirect
1,360,000
$13.41
$18.24M
Invus Public Equities, L.P.
8 Aug 2024
10% owner
Sell
260,873
$0.19
$50.01K
Invus Public Equities, L.P.
7 Aug 2024
10% owner
Sell
61,488
$0.18
$11.20K
Invus Public Equities, L.P.
6 Aug 2024
10% owner
Sell
55,732
$0.18
$10.19K
Invus Public Equities, L.P.
5 Aug 2024
10% owner
Sell
164,523
$0.19
$31.00K
Invus Public Equities, L.P.
2 Aug 2024
10% owner
Sell
286,200
$0.20
$57.35K
Invus Public Equities, L.P.
1 Aug 2024
10% owner
Sell
63,564
$0.22
$13.74K
Invus Public Equities, L.P.
30 Jul 2024
10% owner
Sell
756,835
$0.22
$167.18K
Invus Public Equities, L.P.
29 Jul 2024
10% owner
Sell
363,949
$0.24
$85.64K
Invus Public Equities, L.P.
26 Jul 2024
10% owner
Sell
258,335
$0.24
$62.44K
Rock Edwin
21 Jun 2024
Chief Medical Officer
Buy
115,000
$0.27
$30.72K
Rock Edwin
20 Jun 2024
Chief Medical Officer
Buy
190,000
$0.25
$48.11K
Hahn Brian M.
18 Jun 2024
SVP Finance, CFO
Buy
17,500
$0.25
$4.33K
Rock Edwin
22 Sep 2023
Chief Medical Officer
Buy
30,403
$1.38
$41.96K
Rock Edwin
21 Sep 2023
Chief Medical Officer
Buy
35,000
$1.38
$48.30K
Koenig Scott
1 Jun 2023
Director
Exercised, kept
21,000
$0.60
$12.60K
Hahn Brian M.
17 May 2023
SVP Finance, CFO
Sell
3,700
$1.95
$7.22K
JUNIUS DANIEL M
10 May 2023
Director
Buy
30,000
$1.56
$46.80K
Johnson Bruce S
8 May 2023
SVP & Chief Commercial Officer
Buy
13,500
$1.57
$21.20K
Invus Public Equities, L.P.
24 Feb 2023
10% owner
Buy
100,000
$1.70
$170.00K
Invus Public Equities, L.P.
23 Feb 2023
10% owner
Buy
200,000
$1.75
$350.76K
Invus Public Equities, L.P.
22 Feb 2023
10% owner
Buy
150,000
$1.79
$269.00K
Invus Public Equities, L.P.
21 Feb 2023
10% owner
Buy
50,000
$1.85
$92.50K
Invus Public Equities, L.P.
17 Feb 2023
10% owner
Buy
200,000
$1.71
$341.00K
Invus Public Equities, L.P.
16 Feb 2023
10% owner
Buy
315,266
$1.68
$531.13K
Invus Public Equities, L.P.
15 Feb 2023
10% owner
Buy
1,000,000
$2.16
$2.16M
Invus Public Equities, L.P.
9 Feb 2023
10% owner
Buy
11,451
$3.24
$37.12K
Koenig Scott
27 Jan 2023
Director
Exercised, kept
10,500
$2.55
$26.78K
SANDELL SCOTT D
26 Jan 2023
10% owner
Sell indirect
1,351,092
$3.12
$4.21M
SANDELL SCOTT D
26 Jan 2023
10% owner
Sell indirect
1,648,908
$3.12
$5.14M
SANDELL SCOTT D
25 Jan 2023
10% owner
Sell indirect
293,645
$3.26
$958.43K
SANDELL SCOTT D
25 Jan 2023
10% owner
Sell indirect
358,371
$3.26
$1.17M
SANDELL SCOTT D
5 Jan 2023
10% owner
Sell indirect
32,139
$2.76
$88.66K
SANDELL SCOTT D
5 Jan 2023
10% owner
Sell indirect
39,223
$2.76
$108.20K
SANDELL SCOTT D
4 Jan 2023
10% owner
Sell indirect
45,930
$2.91
$133.64K
SANDELL SCOTT D
4 Jan 2023
10% owner
Sell indirect
56,054
$2.91
$163.10K
SANDELL SCOTT D
3 Jan 2023
10% owner
Sell indirect
78,730
$2.99
$235.41K
SANDELL SCOTT D
3 Jan 2023
10% owner
Sell indirect
96,084
$2.99
$287.30K
SANDELL SCOTT D
30 Dec 2022
10% owner
Sell indirect
54,645
$3.02
$165.03K
SANDELL SCOTT D
30 Dec 2022
10% owner
Sell indirect
66,690
$3.02
$201.40K
Rock Edwin
22 Dec 2022
Chief Medical Officer
Buy
110,000
$2.25
$247.50K
JUNIUS DANIEL M
17 Nov 2022
Director
Buy
20,000
$1.87
$37.40K
Rock Edwin
15 Nov 2022
Chief Medical Officer
Buy
100,000
$1.66
$166.00K
Rock Edwin
14 Nov 2022
Chief Medical Officer
Buy
100,000
$1.43
$143.00K
Girard Armand
11 Nov 2022
SVP, Chief Business Officer
Buy
6,500
$1.05
$6.83K
Magnani John L.
11 Nov 2022
SVP of Research, CSO
Buy
45,045
$1.17
$52.70K
Hahn Brian M.
11 Nov 2022
SVP Finance, CFO
Buy
20,000
$1.06
$21.20K
Semerjian Harout
11 Nov 2022
Chief Executive Officer
Buy
25,000
$1.29
$32.25K
PEARSON TIMOTHY R
11 Nov 2022
Director
Buy
19,400
$1.29
$25.03K
Hahn Brian M.
9 Mar 2022
SVP Finance, CFO
Sell
2,917
$1.09
$3.18K
Girard Armand
9 Mar 2022
SVP, Chief Business Officer
Sell
2,339
$1.09
$2.55K
Magnani John L.
9 Mar 2022
SVP of Research, CSO
Sell
3,227
$1.09
$3.52K
Andrews Patricia S
16 Nov 2021
Director
Buy
40,000
$2.05
$82.00K
King Rachel K.
28 Dec 2020
President, CEO
Sold after exercise
84,176
$3.91
$329.13K
Hahn Brian M.
16 Dec 2020
SVP Finance, CFO
Exercised, kept
5,260
$1.12
$5.89K
BVF PARTNERS L P/IL
4 Nov 2020
10% owner
Buy
86,090
$2.60
$223.83K
BVF PARTNERS L P/IL
4 Nov 2020
10% owner
Buy
506,155
$2.60
$1.32M
BVF PARTNERS L P/IL
4 Nov 2020
10% owner
Buy
674,492
$2.60
$1.75M
BVF PARTNERS L P/IL
30 Oct 2020
10% owner
Buy
15,472
$2.75
$42.55K
BVF PARTNERS L P/IL
30 Oct 2020
10% owner
Buy
250,755
$2.75
$689.58K
BVF PARTNERS L P/IL
30 Oct 2020
10% owner
Buy
666,385
$2.75
$1.83M
JUNIUS DANIEL M
9 Mar 2020
Director
Buy
20,000
$3.40
$68.00K
Magnani John L.
6 Jan 2020
SVP of Research, CSO
Exercised, kept
106,983
$1.12
$119.82K
Magnani John L.
20 Dec 2019
SVP of Research, CSO
Exercised, kept
106,984
$1.12
$119.82K
BVF PARTNERS L P/IL
5 Sep 2019
10% owner
Buy
124,956
$3.18
$397.61K
BVF PARTNERS L P/IL
5 Sep 2019
10% owner
Buy
689,834
$3.18
$2.20M
BVF PARTNERS L P/IL
5 Sep 2019
10% owner
Buy
853,956
$3.18
$2.72M
JUNIUS DANIEL M
13 Aug 2019
Director
Buy
10,000
$3.18
$31.80K
King Rachel K.
6 Aug 2019
President, CEO
Exercised, kept
166,759
$1.12
$186.77K
Magnani John L.
18 Oct 2018
SVP of Research, CSO
Sell
3,527
$14.02
$49.45K
Magnani John L.
17 Oct 2018
SVP of Research, CSO
Sell
7,273
$14.00
$101.82K
Magnani John L.
16 Oct 2018
SVP of Research, CSO
Sell
14,200
$14.01
$198.94K
Hahn Brian M.
11 Jun 2018
CFO
Sold after exercise
19,345
$18.04
$348.98K
Magnani John L.
23 May 2018
SVP of Research, CSO
Exercised, kept
1,491
$0.33
$492.03
NEW ENTERPRISE ASSOCIATES 10 L P
10 May 2018
10% owner
Sold after exercise
5,533
$17.81
$98.54K
NEW ENTERPRISE ASSOCIATES 10 L P
10 May 2018
10% owner
Sold after exercise
4,006
$17.81
$71.35K
BARRETT M JAMES
10 May 2018
Director
Sold after exercise indirect
5,533
$17.81
$98.54K
BARRETT M JAMES
10 May 2018
Director
Sold after exercise indirect
4,006
$17.81
$71.35K
BARRIS PETER J
10 May 2018
10% owner
Sold after exercise indirect
5,533
$17.81
$98.54K
BARRIS PETER J
10 May 2018
10% owner
Sold after exercise indirect
4,006
$17.81
$71.35K
SANDELL SCOTT D
10 May 2018
10% owner
Sold after exercise indirect
5,533
$17.81
$98.54K
SANDELL SCOTT D
10 May 2018
10% owner
Sold after exercise indirect
4,006
$17.81
$71.35K
Thackray Helen M.
8 Dec 2017
SVP Clinical Development, CMO
Sell
2,000
$15.01
$30.02K
Thackray Helen M.
18 Sep 2017
SVP Clinical Development, CMO
Sell
2,000
$13.00
$26.00K
Thackray Helen M.
25 May 2017
SVP Clinical Development, CMO
Sell
2,000
$15.57
$31.14K
Thackray Helen M.
19 May 2017
SVP Clinical Development, CMO
Sell
2,000
$12.14
$24.28K
Magnani John L.
10 May 2017
SVP of Research, CSO
Exercised, kept
8,928
$1.12
$10.00K
JUNIUS DANIEL M
20 Dec 2016
Director
Buy
5,000
$6.01
$30.05K
Thackray Helen M.
3 Oct 2016
VP Clinical Development, CMO
Sell
100
$7.01
$701.00
Thackray Helen M.
3 Oct 2016
VP Clinical Development, CMO
Sell
3,900
$7.00
$27.30K

What was left out

Form 4 filings counted 191
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 17
Sales on a Rule 10b5-1 plan 16
Sales straight out of an exercise 10
Sales at will 34
Transactions with no price 0
Shares from compensation/vesting 4,400,797
Sales filed before the plan box existed 24
History held since 4 Oct 2016